Renaissance Technologies LLC Buys 164,500 Shares of Cronos Group Inc. $CRON

Renaissance Technologies LLC lifted its stake in Cronos Group Inc. (NASDAQ:CRON) by 8.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,009,549 shares of the company’s stock after buying an additional 164,500 shares during the period. Renaissance Technologies LLC’s holdings in Cronos Group were worth $5,044,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Tidal Investments LLC boosted its stake in Cronos Group by 5.3% in the 2nd quarter. Tidal Investments LLC now owns 5,653,070 shares of the company’s stock valued at $10,797,000 after buying an additional 282,356 shares in the last quarter. MMCAP International Inc. SPC lifted its holdings in shares of Cronos Group by 56.1% during the fourth quarter. MMCAP International Inc. SPC now owns 2,761,059 shares of the company’s stock valued at $7,262,000 after acquiring an additional 991,977 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Cronos Group by 6.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,679,051 shares of the company’s stock valued at $6,724,000 after acquiring an additional 172,841 shares during the period. Pillsbury Lake Capital LLC acquired a new stake in shares of Cronos Group in the 4th quarter valued at $4,837,000. Finally, Two Sigma Investments LP grew its holdings in shares of Cronos Group by 229.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,310,386 shares of the company’s stock worth $3,643,000 after purchasing an additional 912,773 shares during the last quarter. Institutional investors own 8.71% of the company’s stock.

Cronos Group Stock Performance

Shares of CRON opened at $3.07 on Friday. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of 307.31 and a beta of 0.90. The business’s fifty day moving average price is $2.77 and its two-hundred day moving average price is $2.67. Cronos Group Inc. has a 52 week low of $2.14 and a 52 week high of $3.43.

Cronos Group (NASDAQ:CRON) last released its earnings results on Monday, May 11th. The company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $45.21 million during the quarter, compared to analysts’ expectations of $42.20 million. Cronos Group had a negative return on equity of 1.26% and a negative net margin of 1.14%. As a group, research analysts forecast that Cronos Group Inc. will post 0.07 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on CRON. TD Securities reissued a “buy” rating on shares of Cronos Group in a report on Tuesday, May 12th. Wall Street Zen upgraded Cronos Group from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Cronos Group in a report on Friday, May 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Cronos Group presently has an average rating of “Hold” and an average target price of $2.30.

Cronos Group News Roundup

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Cronos reported record second-quarter organic revenue, gross profit and adjusted EBITDA. Organic, constant-currency revenue increased 51% year over year, while adjusted EBITDA reached $13.1 million. Cronos Group Reports 2026 Second Quarter Results
• Positive Sentiment: The company exceeded quarterly expectations, reporting earnings of approximately $0.03 to $0.09 per share versus a consensus estimate of $0.01. Revenue was $53.01 million, above the $44.20 million analyst forecast. Cronos Group Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Growth was broad-based: Spinach maintained the No. 1 position in Canadian vapes and edibles, PEACE NATURALS continued its leading position in Israel, and demand in Germany helped drive record revenue outside Canada and Israel.
• Positive Sentiment: Cronos repurchased 12.3 million shares during the first half of 2026, reducing the share count and potentially supporting per-share results.
• Positive Sentiment: The planned acquisition of CanAdelaar is expected to close in the second half of 2026, potentially adding to Cronos’ growth and operating scale. Cronos CanAdelaar Acquisition and Q2 Adjusted EBITDA
• Neutral Sentiment: Despite the earnings beat, Cronos remained marginally unprofitable, with a negative net margin and negative return on equity. Investors will likely focus on whether the improved adjusted EBITDA converts into sustained net profitability.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.